Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Merck Sharp & Dohme (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (138)
ARTG (79)
Prescription medicine registration (61)
Australian public assessment report (AusPar) (33)
Designation or determination (31)
Prescription medicine evaluation (4)
Prescription medicine decision summary (2)

Date

2025 (35)
2024 (23)
2023 (32)
2022 (29)
2021 (31)
2020 (37)
2019 (52)
2018 (23)
2017 (3)
2016 (10)
2015 (6)
2014 (9)
2013 (13)
2012 (6)
2011 (4)
2009 (10)
2008 (1)
2007 (2)
2006 (8)
2005 (1)
2003 (1)
2002 (3)
2000 (1)
1998 (1)
1997 (5)
1993 (1)
1991 (1)

Search

Sponsor content

348 result(s) found, displaying 21 to 30

BRIDION sugammadex 500 mg/5 mL solution for injection vial Cancelled under Section 30(1)(c) of the Act

9 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
BRIDION sugammadex 200 mg/2 mL solution for injection vial Cancelled under Section 30(1)(c) of the Act

9 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STOCRIN efavirenz 600mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

4 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STOCRIN efavirenz 300mg tablet bottle Cancelled under Section 30(1)(c) of the Act

4 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STOCRIN efavirenz 300mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

4 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STOCRIN efavirenz 600mg tablet bottle Cancelled under Section 30(1)(c) of the Act

4 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STOCRIN efavirenz 50mg tablet bottle Cancelled under Section 30(1)(c) of the Act

4 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
SEVELON efavirenz 600 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

4 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
STOCRIN efavirenz 200mg tablet bottle Cancelled under Section 30(1)(c) of the Act

4 April 2025

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
TRADEMARK (TO BE ADVISED) Merck Sharp & Dohme (Australia) Pty Ltd

Mar-2025

Prescription medicine evaluation

Active ingredient: clesrovimab.

Pages

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.